Jun 29, 2007 07:05 ET
Medistem Laboratories Announces Positive Preclinical Results for MDS-
786 Candidate
Non-Toxic Treatment for Lung Cancer Presented at International Stem
Cell Meeting
PHOENIX, AZ--(Marketwire - June 29, 2007) - Medistem Laboratories
(OTCBB: MDSM) (FRANKFURT: S2U) announced today preclinical proof-of-
concept studies demonstrating the positive potential of the company's
MDS-786 candidate drug for lung cancer. The findings were presented
at the 13th Annual Meeting of the International Society for Cellular
Therapy that took place June 24-27, 2007 in Sydney, Australia. The
presentation, entitled "Differentiation and Inhibition of Tumor Cells
by Cord Blood Stem Cells" reviewed the ability of MDS-786 to induce a
process called "differentiation" in which tumor cells are coaxed into
transforming into non-tumor cells through the use of a placentally
derived product.
Thomas Ichim, Medistem's Chief of Scientific Development and primary
author of the paper, stated, "To date, treatment options for patients
with lung cancer are primarily limited to highly toxic chemotherapy
and radiotherapy approaches, which in many cases are not successful.
Through harnessing molecular mechanisms that signal stem cell
maturation in normal cells, we are inducing a process that drives
malignant cells to convert into non-malignant cells." He
continued, "The process of inducing malignant cells to transform into
normal cells has been proven clinically as a viable treatment for
cancer and is used in the treatment of patients with Acute
Promyelocytic Leukemia. By applying such a process to solid tumors,
we believe numerous therapeutic applications may exist that lack the
toxicity of current approaches."
The National Cancer Institute estimates that over 10 million people
are diagnosed with cancer annually. While there are some viable
options today for treating some forms of cancer, Medistem is hopeful
that MDS-786 can begin to address this dreaded disease in a non-toxic
manner by allowing stem cells and the immune system to work in
concert with one another to achieve homeostasis.
http://www.marketwi
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:
Children's Neurobiological Solutions
http://www.CNSfoundation.org/
Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123
The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Earn your degree in as few as 2 years - Advance your career with an AS, BS, MS degree - College-Finder.net.
Earn your degree in as few as 2 years - Advance your career with an AS, BS, MS degree - College-Finder.net.
Change settings via the Web (Yahoo! ID required)
Change settings via email: Switch delivery to Daily Digest | Switch format to Traditional
Visit Your Group | Yahoo! Groups Terms of Use | Unsubscribe
__,_._,___
